UTHR Share Price

Open 130.05 Change Price %
High 132.18 1 Day 1.51 1.16
Low 129.85 1 Week 1.53 1.18
Close 131.49 1 Month -0.10 -0.08
Volume 378275 1 Year 19.36 17.27
52 Week High 169.89
52 Week Low 110.90
UTHR Important Levels
Resistance 2 133.65
Resistance 1 132.76
Pivot 131.17
Support 1 130.22
Support 2 129.33
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
TOPS 0.44 69.23%
More..
NASDAQ USA Top Gainers Stocks
TOPS 0.44 69.23%
SCHS 0.05 66.67%
ELTK 0.95 53.23%
LOCM 0.09 50.00%
SGMS 34.15 27.19%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
MTSL 0.64 20.75%
WBMD 66.10 19.77%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CYTX 0.48 -56.76%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

United Therapeutics Corporation (NASDAQ: UTHR)

UTHR Technical Analysis 2
As on 24th Jul 2017 UTHR Share Price closed @ 131.49 and we RECOMMEND Sell for LONG-TERM with Stoploss of 132.86 & Strong Buy for SHORT-TERM with Stoploss of 127.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
UTHR Target for July
1st Target up-side 136.71
2nd Target up-side 141.6
3rd Target up-side 146.5
1st Target down-side 122.75
2nd Target down-side 117.86
3rd Target down-side 112.96
UTHR Other Details
Segment EQ
Market Capital 2447069440.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.unither.com
UTHR Address
UTHR
1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 301-608-9292
Fax: 301-608-9291
Interactive Technical Analysis Chart United Therapeutics Corporation ( UTHR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on United Therapeutics Corporation
UTHR Business Profile
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung Tissue for Transplantation. Prostacyclin analogues are stable synthetic forms of prostacyclin. Its product is Remodulin (treprostinil) Injection (Remodulin). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of pulmonary arterial hypertension (PAH). MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells.